About the Company
We do not have any company description for Cullinan Therapeutics, Inc. at the moment.
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest News on Cullinan Therapeutics, Inc.
Cullinan Therapeutics to Participate in Upcoming Investor Conferences
Cullinan Therapeutics, Inc. (Nasdaq: CGEM; “Cullinan”), a biopharmaceutical company focused on developing modality-agnostic ...
Cullinan Therapeutics to Host Analyst and Investor Event at ... - Nasdaq
--Cullinan Therapeutics, Inc., a biopharmaceutical company focused on developing modality-agnostic targeted therapies, today announced its management team will host a company event at the 2025 ...
CGEM - Cullinan Therapeutics Inc News | Morningstar
Cullinan Therapeutics Inc CGEM Stock XNAS Rating as of Aug 1, 2025 Summary Chart News Price vs Fair Value Sustainability Trailing Returns Key Metrics Financials Valuation Dividends Ownership Executive ...
Cullinan Therapeutics to Present Positive REZILIENT1 Study ... - Nasdaq
Cullinan Therapeutics, Inc. announced that it will present results from the REZILIENT1 study of zipalertinib, a treatment for non-small cell lung cancer (NSCLC) patients with EGFR exon 20 ...
Cullinan Therapeutics Announces Oversubscribed $280 million Private ...
About Cullinan Therapeutics Cullinan Therapeutics, Inc. (Nasdaq: CGEM) is a biopharmaceutical company dedicated to creating new standards of care for patients.
Cullinan Therapeutics Inc. Stock Grades | CGEM | Barron's
About Cullinan Therapeutics Inc. Cullinan Oncology is a developer of an externally sourced cancer therapeutics intended to end a drug program quickly if the early research suggests it won't work.
Cullinan Therapeutics Presents Positive Updated Data from Module C of ...
Enrollment of pivotal Phase 2b trial complete ahead of schedule CAMBRIDGE, Mass., Sept. 14, 2024 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused ...
CGEM Cullinan Therapeutics, Inc. - Seeking Alpha
Cullinan Therapeutics, Inc. (CGEM) key stats comparison: compare with other stocks by metrics: valuation, growth, profitability, momentum, EPS revisions, dividends ...
Tower Research Capital LLC TRC Grows Stock Holdings in Cullinan ...
Cullinan Therapeutics, Inc. has a 52 week low of $6.85 and a 52 week high of $29.08. The stock has a market cap of $459.55 million, a PE ratio of -2.74 and a beta of -0.07.
CGEM | Cullinan Therapeutics Inc. Stock Price & News - WSJ
View the latest Cullinan Therapeutics Inc. (CGEM) stock price, news, historical charts, analyst ratings and financial information from WSJ.
CGEM - Cullinan Therapeutics Inc Chart | Morningstar
Cullinan Therapeutics Inc CGEM Stock XNAS Rating as of Mar 12, 2025 Download PDF Summary Chart News Price vs Fair Value Sustainability Trailing Returns Key Metrics Financials Valuation Dividends ...
Similar Companies
Loading the latest forecasts...